
X
AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancer
https://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/
AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.
Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.